The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EORTC CLTF 2021 | Updates on the brentuximab vedotin for CTCL
Chalid Assaf, MD, PhD, Helios Klinikum Krefeld, Krefeld, Germany, discusses the latest updates in the treatment of cutaneous T-cell lymphoma (CTCL), in particular highlighting the use of brentuximab vedotin in patients with late-stage disease, and questioning the importance of CD30 positivity in its use. Dr Assaf reports that CTCL tumor samples expressing below 10% of CD30 were found to have very good responses to brentuximab vedotin. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.
